Fig. 3.

Assessment of imaging evaluation by patient after tocilizumab treatment for 96 weeks (N = 28)

(A) Change from baseline in the condition of arteries in patients treated with tocilizumab for 96 weeks. (B) Outcomes for wall thickness, dilatation/aneurysm, stenosis/occlusion, and wall enhancement after 96 weeks of tocilizumab treatment. ^aPatients who experienced relapse of Takayasu arteritis during 96 weeks of tocilizumab treatment: Y: yes; N: no. Imaging data were evaluated at 96 weeks (day 673; range, days 505–841). If multiple scans were available during the time window, the scan conducted closest to the scheduled date was used.